title: Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
abstract: OBJECTIVE
  Inhibition of bradykinin metabolizing enzymes (BMEs) can cause acute angioedema, as demonstrated in a recent clinical trial in patients administered the antihypertensive, omapatrilat. However, the relative contribution of specific BMEs to this effect is unclear and confounded by the lack of a predictive pre-clinical model of angioedema.
  
  
  METHODS
  Rats were instrumented to record blood pressure and heart rate; inhibitors were infused for 35 min and bradykinin was infused during the last 5 min to elicit hypotension, as a functional marker of circulating bradykinin and relative angioedema risk.
  
  
  RESULTS
  In the presence of omapatrilat bradykinin produced dose-dependent hypotension, an effect abolished by B(2) blockade. In the presence of lisinopril (ACE inhibitor), but not candoxatril (NEP inhibitor) or apstatin (APP inhibitor), bradykinin also elicited hypotension. Lisinopril-mediated hypotension was unchanged with concomitant blockade of NEP or NEP/DPPIV (candoxatril+A-899301). However, hypotension was enhanced upon concomitant blockade of APP and further intensified in the presence of NEP inhibition to values not different from omapatrilat alone.
  
  
  CONCLUSIONS
  We demonstrated that bradykinin is degraded in vivo with an enzyme rank-efficacy of ACE>APP>>NEP or DPPIV. These results suggest the effects of omapatrilat are mediated by inhibition of three BMEs, ACE/APP/NEP. However, dual inhibition of ACE/NEP or ACE/NEP/DPPIV elicits no increased risk of angioedema compared to ACE inhibition alone. Thus, novel BME inhibitors must display no activity against APP to avoid angioedema risk due to high prevalence of ACE inhibitor therapy in patients with diabetes and cardiovascular disease.
authors: Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6119, USA. ryan.fryer@abbott.com
authors: R M
authors: RM
authors: Fryer
authors: J
authors: J
authors: Segreti
authors: P N
authors: PN
authors: Banfor
authors: D L
authors: DL
authors: Widomski
authors: B J
authors: BJ
authors: Backes
authors: C W
authors: CW
authors: Lin
authors: S J
authors: SJ
authors: Ballaron
authors: B F
authors: BF
authors: Cox
authors: J M
authors: JM
authors: Trevillyan
authors: G A
authors: GA
authors: Reinhart
authors: T W
authors: TW
authors: von Geldern
mesh_terms: D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000799:Angioedema / Q000209:etiology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007022:Hypotension / Q000209:etiology*; D007189:Indans / Q000494:pharmacology; D017706:Lisinopril / Q000494:pharmacology; D008297:Male; D015260:Neprilysin / Q000037:antagonists & inhibitors; D010455:Peptides / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013841:Thiazepines / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004791:Enzyme Inhibitors; D007189:Indans; D010455:Peptides; D011422:Propionates; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; C062766:candoxatril; D017706:Lisinopril; D000626:Aminopeptidases; C022750:X-Pro aminopeptidase; D015260:Neprilysin; C097277:apstatin; D001920:Bradykinin